188 related articles for article (PubMed ID: 10780524)
1. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Wass JA; Harris AL
Br J Cancer; 2000 Apr; 82(8):1441-5. PubMed ID: 10780524
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
J Endocrinol; 2000 May; 165(2):475-81. PubMed ID: 10810311
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Mar; 85(3):1159-62. PubMed ID: 10720055
[TBL] [Abstract][Full Text] [Related]
4. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland.
Turner HE; Nagy Z; Sullivan N; Esiri MM; Wass JA
Clin Endocrinol (Oxf); 2000 Sep; 53(3):337-44. PubMed ID: 10971451
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of markers of cell proliferation in the management of pituitary adenomas.
Losa M; Franzin A; Mortini P; Terreni MR; Mangili F; Giovanelli M
Clin Sci (Lond); 1998 Aug; 95(2):129-35. PubMed ID: 9680493
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
[TBL] [Abstract][Full Text] [Related]
11. Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis.
Aotake T; Lu CD; Chiba Y; Muraoka R; Tanigawa N
Clin Cancer Res; 1999 Jan; 5(1):135-42. PubMed ID: 9918211
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
13. Role of matrix metalloproteinase 9 in pituitary tumor behavior.
Turner HE; Nagy Z; Esiri MM; Harris AL; Wass JA
J Clin Endocrinol Metab; 2000 Aug; 85(8):2931-5. PubMed ID: 10946906
[TBL] [Abstract][Full Text] [Related]
14. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer.
Perrone G; Vincenzi B; Santini D; Verzì A; Tonini G; Vetrani A; Rabitti C
Cancer Lett; 2004 May; 208(2):227-34. PubMed ID: 15142682
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
Onofri C; Losa M; Uhl E; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis in pituitary adenomas.
Yamada S; Takada K
Microsc Res Tech; 2003 Feb; 60(2):236-43. PubMed ID: 12539178
[TBL] [Abstract][Full Text] [Related]
17. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
18. Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.
Hou XZ; Liu W; Fan HT; Liu B; Pang B; Xin T; Xu SC; Pang Q
Neuro Oncol; 2010 Aug; 12(8):799-803. PubMed ID: 20200025
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus.
Koide N; Nishio A; Hiraguri M; Hanazaki K; Adachi W; Amano J
Am J Gastroenterol; 2001 Jun; 96(6):1733-40. PubMed ID: 11419822
[TBL] [Abstract][Full Text] [Related]
20. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
